B-cell prolymphocytic leukemia successfully treated with B-cell receptor antagonists, but resistant to venetoclax-Reference-Cited by-同舟云学术

B-cell prolymphocytic leukemia successfully treated with B-cell receptor antagonists, but resistant to venetoclax

Published:2019-11-12 Issue:3 Volume:61 Page:749-752
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Christoforidou Anna¹,Bezirgiannidou Zoe¹,Vrachiolias George¹,Papoutselis Menelaos¹,Spanoudakis Emmanouil¹,Kotsianidis Ιoannis¹

Affiliation:

1. Department of Haematology, Democritus University of Thrace, Alexandroupolis, Greece

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2019.1689392

Reference15 articles.

1. B- and T-cell prolymphocytic leukemia: antibody approaches

2. Management of prolymphocytic leukemia

3. Campo EME, Montserrat E, Harris NL, et al. editor. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon (France): IARC Press; 2017. p. 222–223.

4. p53 Abnormalities in B-Cell Prolymphocytic Leukemia

5. Genetic Characterization of B-Cell Prolymphocytic Leukemia (B-PLL): A Hierarchical Prognostic Model Involving MYC and TP53 Abnormalities. on Behalf of the Groupe Francophone De Cytogenetique Hematologique (GFCH) and the French Innovative Leukemia Organization (FILO) Group

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Venetoclax induces deep and durable minimal residual disease‐negative remission in high‐risk TP53 disrupted B prolymphocytic leukaemia;European Journal of Haematology;2022-08-05

2. Zanubrutinib, rituximab and lenalidomide induces deep and durable remission in TP53 mutated B-cell prolymphocytic leukemia: a case report and review of literature;Haematologica;2021-12-23

3. An Unusual Case of Prolymphocytic Leukemia Transformation in a Patient With Chronic Lymphocytic Leukemia;Journal of Investigative Medicine High Impact Case Reports;2021-01

4. Dabigatran-etexilate/venetoclax;Reactions Weekly;2020-04